CSF3 and non-Hodgkin lymphoma: Several studies have suggested that G-CSF prophylaxis strategy following chemotherapy for all NHL patients at high risk for FN (> 20%) decreases morbidity and mortality, and our systematic review underpins these recommendations [4, 18, 32, 34].